finasteride has been researched along with Metabolic Syndrome in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Culig, Z; Madersbacher, S; Sampson, N | 1 |
| Guay, AT; Traish, AM; Zitzmann, M | 1 |
| Cyrus, A; Farmani, E; Goodarzi, D; Kabir, A; Moghimi, M; Moradi, A; Rafiee, M; Shahbazi, E; Talaei, A | 1 |
2 review(s) available for finasteride and Metabolic Syndrome
| Article | Year |
|---|---|
Pathophysiology of Benign Prostatic Hyperplasia and Benign Prostatic Enlargement: A Mini-Review.
Topics: 3-Oxo-5-alpha-Steroid 4-Dehydrogenase; 5-alpha Reductase Inhibitors; Aging; Diabetes Mellitus; Dihydrotestosterone; Dutasteride; Dyslipidemias; Finasteride; Humans; Inflammation; Lower Urinary Tract Symptoms; Male; Metabolic Syndrome; Prostatic Hyperplasia; Receptors, Androgen | 2019 |
5α-Reductase inhibitors alter steroid metabolism and may contribute to insulin resistance, diabetes, metabolic syndrome and vascular disease: a medical hypothesis.
Topics: 5-alpha Reductase Inhibitors; Animals; Azasteroids; Diabetes Mellitus; Dutasteride; Finasteride; Glucocorticoids; Humans; Insulin Resistance; Metabolic Syndrome; Mineralocorticoids; Obesity; Vascular Diseases | 2014 |
1 other study(ies) available for finasteride and Metabolic Syndrome
| Article | Year |
|---|---|
Impact of metabolic syndrome on response to medical treatment of benign prostatic hyperplasia.
Topics: Aged; Case-Control Studies; Finasteride; Humans; Lower Urinary Tract Symptoms; Male; Metabolic Syndrome; Middle Aged; Patient Selection; Prazosin; Prostatic Hyperplasia; Treatment Outcome; Urological Agents | 2014 |